Key Drivers
- High liquidity
- Persistent losses
- Negative cash flow
AIAI Summary
Trevi has transitioned from an early‑stage bet to a de‑risking, regulatory‑execution story where value now hinges on disciplined Phase 3 execution, completion of required DDI/safety work, and preserving cash runway rather than on scientific validation. Monitor three binary triggers for action: (1) clear cash runway or a non‑dilutive partner through Phase 3, (2) timely completion of CYP2C9/2C19 DDI and 52‑week safety collection with no new signals, and (3) on‑time enrollment/endpoint acceptance — failure on any materially increases downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Persistent losses
- •Negative cash flow
TRVI has a very strong liquidity and low leverage cushion (cash + investments ≈ $188M, current ratio 19.7, debt/equity 0.06) but no revenue, large operating losses and negative cash flow signal ongoing burn and valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Below last-month MA
- •RSI near-30
- •Sharp early-March drop
TRVI is short-term negative—trading below its last-month average after a sharp March 6–20 drop, with RSI near 30 suggesting selling dominance but possible short-term exhaustion and resistance near the mid-teens versus support near the low tens.
Sharp decline from
Sentiment & News
Key News Insights:
- •Phase 3 alignment
- •Clinical momentum
- •Analyst attention
Trevi secures FDA alignment for Phase 3 nalbuphine ER in IPF-related chronic cough, reports positive clinical momentum and rising analyst/investor interest that could drive re-rating.
This positions Trevi for near-term valuation upside as Phase 3-readiness and investor engagement increase the likelihood of upside catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings